drugset / Trial / NCT00634985

Safety and Efficacy of Eletriptan for the Treatment of Migraine in Subjects Unsuccessfully Treated With Nonsteroidal Anti-inflammatory Drugs

NCT00634985

Phase 4 Completed 120 enrolled Viatris Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To assess the safety and efficacy of eletriptan for the treatment of migraine in subjects who had not been adequately treated with non-steroidal antiinflammatory drugs (NSAIDs)

Timeline

Start
2002-11
Primary completion
Completion
2003-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Eletriptan Small molecule 40 mg Oral

Indications